Mikko Lemola/iStock through Getty Photos
Biotech group AN2 Therapeutics (ANTX) has filed to carry an preliminary public providing to assist fund growth of its drug candidate for a uncommon lung illness.
The corporate stated it intends to record its inventory on the Nasdaq below the image ANTX. The dimensions and pricing of the deal weren’t disclosed in the filing.
Cowen, SVB Leerink, Evercore ISI and Oppenheimer are serving as bookrunners on the deal.
AN2 Therapeutics is creating a remedy known as epetraborole for the remedy of nontuberculous mycobacterial, or NTM, lung illness. The product is presently in Section I testing.
A growth stage firm, AN2 reported a web lack of $22M with no income for 2021.
For extra IPO information, take a look at SA’s IPO News page.
